New eye injection shows promise for wet AMD in everyday practice
NCT ID NCT07640997
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 300 people with wet age-related macular degeneration (nAMD) who receive aflibercept 8 mg injections as part of their routine care. Researchers want to see how well the drug improves vision and reduces retinal swelling over 12 months, and what side effects occur. The study includes both new and previously treated patients, and all treatment decisions are made by their own doctors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aflibercept 8 mg (eye injection)
- What this could lead to
- If successful, this study could confirm that aflibercept 8 mg works well in everyday practice for treating wet age-related macular degeneration, potentially improving vision for many patients.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. The drug is already approved, so the main question is about real-world effectiveness, not a breakthrough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be enrolled in eye clinics or ophthalmology practices
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient aged ≥50 years * A diagnosis of nAMD * Signed informed patient consent before the start of data collection * Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice Exclusion Criteria: * Participation in an investigational program with interventions outside of clinical routine practice * Contraindications as listed in the intravitreal aflibercept 8 mg local product information (Ocular or periocular infections, severe active intraocular inflammation, and known allergy to aflibercept or any of its excipients) * The fellow eye has received intravitreal anti-VEGF treatment other than aflibercept within 28 days prior to enrollment * Intraocular pressure (IOP) in the study eye \> 25 mmHg * Additional exclusion criteria for naïve nAMD patients: * Any prior ocular treatment in the study eye or systemic treatment for nAMD * Additional exclusion criteria for pretreated nAMD patients: * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months * Dexamethasone implant in the study eye within the last 6 months * Any concurrent drug releasing implant in the study eye
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
27 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Affiliated Hospital Of Zunyi Medical University
NOT_YET_RECRUITINGZunyi, Guizhou, China
-
Beijing CHAO-YANG Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Beijing Haidian Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Dalian No.3 People's Hospital
RECRUITINGDalian, Liaoning, China
-
Jinan Second People's Hospital
NOT_YET_RECRUITINGJinan, Shandong, China
-
Nanyang Eye Hospital
RECRUITINGNanyang, Henan, China
-
Ningbo Eye Hospital
NOT_YET_RECRUITINGNingbo, Zhejiang, China
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Peking University First Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
-
Peking University Third Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Qingdao Eye Hospital Of Shandong First Medical University
NOT_YET_RECRUITINGQingdao, Shandong, China
-
Shanghai Tenth People's Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
-
Shenzhen Eye Hospital
NOT_YET_RECRUITINGShenzhen, Guangdong, China
-
Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, China
-
TONG REN Hospital, Shanghai Jiao Tong University School Of Medicine
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
-
The 2nd Affiliated Hospital of Harbin Medical University
NOT_YET_RECRUITINGHarbin, Heilongjiang, China
-
The Affiliated Hospital of Inner Mongolia Medical University
NOT_YET_RECRUITINGHohhot, Inner Mongolia, China
-
The First Affiliated Hospital Of Fujian Medical University
NOT_YET_RECRUITINGFuzhou, Fujian, China
-
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITINGWenzhou, Zhejiang, China
-
The Fourth People's Hospital Of Shenyang
NOT_YET_RECRUITINGShenyang, Liaoning, China
-
Tianjin Medical University Eye Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, China
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, China
-
Tongji Hospital Tongji Medical College of HUST
NOT_YET_RECRUITINGWuhan, Hubei, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, China
-
Xi'an People's Hospital
NOT_YET_RECRUITINGXi'an, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can fewer eye injections dry the retina in wet AMD?
- The 20-Minute squeeze: how eye injections push pressure up
- Could years of eye injections weigh down the upper eyelid?
- One eye injection, four targets: GenSci148 tested against retinal swelling
- One shot in the eye: gene therapy aims to replace repeated injections for wet AMD
- Can a new eye injection beat the standard for wet AMD?